John Wood sees Government Defence and Green Energy Reviews as positive for InfraStrata #INFA Watch Now

Less Ads, More Data, More Tools Register for FREE
John Wood sees Government Defence and Green Energy Reviews as positive for InfraStrata #INFA
John Wood sees Government Defence and Green Energy Reviews as positive for InfraStrata #INFAView Video
Hardman & Co Mining Forum: Scotgold #SGZ prepare for production at Scottish gold/silver mine
Hardman & Co Mining Forum: Scotgold #SGZ prepare for production at Scottish gold/silver mineView Video

UPDATE 1-GlaxoSmithKline CEO optimistic COVID-19 vaccine widely available in 2021

Tue, 29th Sep 2020 20:34

* Mass rollout would be challenging, GSK chief Walmsley says

* She says immunisation development speed does not reduce
safety
(Adds remarks on vaccine safety)

By Ludwig Burger

FRANKFURT, Sept 29 (Reuters) - The chief executive of
GlaxoSmithKline, the world's largest maker of vaccines,
said she was optimistic the industry will be able to make an
immunisation against COVID-19 widely available next year.

"I share the optimism that we will have solutions next year.
The challenge here is getting to the scale that is required,"
GSK CEO Emma Walmsley said at an online event of the
Confederation of British Industry (CBI) on Tuesday.

GSK is contributing adjuvants, efficacy boosters that play a
vital role in many vaccines, in several development alliances
for potential future vaccines against the novel coronavirus that
has claimed more than a million lives globally.

The group's most advanced project is with French partner
Sanofi and the two have said they hope to get approval
for their candidate next year.

Walmsley stressed the industry's unprecedented speed of
developing an immunisation did not compromise safety because
trials were not smaller than usual and regulators and companies
were taking steps in parallel that were previously done
consecutively.

"We are condensing timelines that can take 10 years into two
years. But people should feel very reassured that the way we do
that is (due to) a completely different level of collaboration
with regulators," the CEO said.

"We are putting our funds at risk, governments have put
funds at risk so that we don’t restrict the scale, which is
really important in a trial for vaccines," she added.
(Reporting by Ludwig Burger, Editing by Franklin Paul and Grant
McCool)

Related Shares

More News

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

20 Nov 20 08:34

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

19 Nov 20 20:25

Glaxo, Pfizer's HIV Tablet Treatment Gets Positive Opinion In EU

Glaxo, Pfizer's HIV Tablet Treatment Gets Positive Opinion In EU

13 Nov 20 14:34

UK BROKER RATINGS SUMMARY: Barclays Raises Whitbread To Overweight

UK BROKER RATINGS SUMMARY: Barclays Raises Whitbread To Overweight

13 Nov 20 09:39

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.